title: The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.
abstract: OBJECTIVE
  The impact of infliximab induction and maintenance therapy on health-related quality of life (HRQL) was evaluated in patients with ulcerative colitis (UC).
  
  
  METHODS
  In two placebo-controlled, double-blind studies (the Active Ulcerative Colitis Trials 1 and 2 [ACT 1 and 2]), 728 patients were randomized to placebo or infliximab 5 mg/kg or 10 mg/kg. Infusions were administered at weeks 0, 2, 6, and every 8 wk thereafter, up to week 22 (ACT 2) or 46 (ACT 1). Changes in Inflammatory Bowel Disease Questionnaire (IBDQ) and Medical Outcomes Study 36-Item Short Form Health Survey physical and mental component summary (PCS and MCS, respectively) scores were analyzed.
  
  
  RESULTS
  Baseline scores for the pooled patient population indicated substantial impairment in HRQL. Improvement at week 8 in the total IBDQ score was significantly greater in the infliximab 5-mg/kg (40, P < 0.001) and 10-mg/kg (36, P < 0.001) groups compared with the placebo group (28). Improvement at week 8 was also significantly greater in the infliximab 5- and 10-mg/kg groups for the PCS (6.8 and 5.9, respectively) and MCS (5.9 and 6.4, respectively) compared with placebo (PCS = 3.7, MCS = 3.0, P < 0.01 for all comparisons). Continued benefit was seen at weeks 30 and 54 with infliximab maintenance therapy (P < 0.001 for all comparisons). Improvement in total IBDQ score correlated significantly (P < 0.001) with improvement in both PCS and MCS scores, and Mayo score.
  
  
  CONCLUSIONS
  Infliximab therapy substantially improved HRQL in patients with UC. This benefit was sustained through 1 yr with maintenance infliximab therapy.
authors.affiliation: Robarts Research Institute, University of Western Ontario, London, Canada.
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
authors.forename: Walter
authors.initials: W
authors.lastname: Reinisch
authors.forename: Paul
authors.initials: P
authors.lastname: Rutgeerts
authors.forename: William J
authors.initials: WJ
authors.lastname: Sandborn
authors.forename: Songkai
authors.initials: S
authors.lastname: Yan
authors.forename: Debra
authors.initials: D
authors.lastname: Eisenberg
authors.forename: Mohan
authors.initials: M
authors.lastname: Bala
authors.forename: Jewel
authors.initials: J
authors.lastname: Johanns
authors.forename: Allan
authors.initials: A
authors.lastname: Olson
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Hanauer
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D010919:Placebos; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D010919:Placebos; D000069285:Infliximab